MCID: PRM126
MIFTS: 53

Primary Peritoneal Carcinoma malady

Cancer diseases, Rare diseases categories

Aliases & Classifications for Primary Peritoneal Carcinoma

About this section
Sources:
48Orphanet, 61UMLS, 26ICD10 via Orphanet
See all sources

Aliases & Descriptions for Primary Peritoneal Carcinoma:

Name: Primary Peritoneal Carcinoma 48 61
Serous Surface Papillary Carcinoma 48 61
Extra-Ovarian Primary Peritoneal Carcinoma 48
Primary Peritoneal Serous Adenocarcinoma 61
 
Primary Peritoneal Serous Carcinoma 48
Eoppc 48
Ppc 48


Classifications:

Orphanet: 48 
Rare tumors


Characteristics (Orphanet epidemiological data):

48
serous surface papillary carcinoma:
Age of onset: Adult; Age of death: normal life expectancy


External Ids:

Orphanet48 168829
ICD10 via Orphanet26 C48.2

Summaries for Primary Peritoneal Carcinoma

About this section
Wikipedia:64 Primary peritoneal cancer or carcinoma is also known as: serous surface papillary carcinoma, primary... more...

MalaCards based summary: Primary Peritoneal Carcinoma, also known as serous surface papillary carcinoma, is related to peritoneal carcinoma and papillary carcinoma, and has symptoms including weight loss, nausea and vomiting and constipation. An important gene associated with Primary Peritoneal Carcinoma is BRCA1 (breast cancer 1, early onset), and among its related pathways are Homologous Recombination Repair and DNA Damage Induced 14-3-3Sigma Signaling. The compounds topotecan and vinorelbine have been mentioned in the context of this disorder. Affiliated tissues include ovary, brain and eye, and related mouse phenotypes are liver/biliary system and renal/urinary system.

Related Diseases for Primary Peritoneal Carcinoma

About this section

Diseases in the Peritoneal Carcinoma family:

Peritoneal Benign Neoplasm primary peritoneal carcinoma

Diseases related to Primary Peritoneal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 125)
idRelated DiseaseScoreTop Affiliating Genes
1peritoneal carcinoma32.3BRCA2, BRCA1
2papillary carcinoma30.8RET, ERBB2, MUC16, PGR, BRCA2
3tuberculosis30.5IFNG, CXCL10, IL10
4endometriosis30.3PGR, IL8, MUC16
5adenocarcinoma29.1ERBB2, EGFR, CEACAM5, CXCL10, MUC16, PGR
6peritonitis11.1
7struma ovarii10.5MUC16
8adenofibroma10.5MUC16
9hereditary breast ovarian cancer10.5BRCA2
10ovarian serous cystadenocarcinoma10.5MUC16
11papillary serous adenocarcinoma10.5
12pleurisy10.5MUC16
13cystadenoma10.5BRCA1
14uterine fibroid10.5PGR
15cystadenocarcinoma10.5MUC16, CEACAM5
16papillary adenocarcinoma10.4MUC16, CEACAM5
17brca1 and brca2 hereditary breast and ovarian cancer10.4BRCA1, BRCA2
18endodermal sinus tumor10.4CEACAM5, MUC16
19fallopian tube cancer10.4BRCA1, BRCA2
20breast cancer10.4BRCA1, BRCA2
21neuroblastoma10.4TP53
22ovarian cystadenoma10.4MUC16, BRCA1
23lynch syndrome10.4BRCA1, BRCA2
24paracoccidioidomycosis10.4IL10, CXCL10
25meningitis10.3IL8, CXCL10
26dysgerminoma10.3BRCA2, BRCA1
27sex cord-gonadal stromal tumor10.3PGR, CEACAM5
28autosomal dominant disease10.3RET, BRCA1
29viral meningitis10.3CXCL10, IL8
30mammary paget's disease10.3ERBB2, PGR
31ovary papillary carcinoma10.3
32breast disease10.3PGR, ERBB2
33bronchiolitis obliterans10.3CXCL10, IL8
34hepatitis10.3
35ovarian serous carcinoma10.3
36in situ carcinoma10.3
37syphilis10.3
38tertiary syphilis10.3
39cervical adenocarcinoma10.3CEACAM5, MUC16, PGR
40folliculitis10.3EGFR
41cowden disease10.3BRCA2, BRCA1, RET
42bilateral breast cancer10.2PGR, BRCA2, BRCA1
43gynecomastia10.2PGR, BRCA2, BRCA1
44gallbladder cancer10.2CEACAM5, TP53
45alcoholic hepatitis10.2IL10, IL8
46tubular adenocarcinoma10.2PGR, CEACAM5, ERBB2
47gastric adenocarcinoma10.2ERBB2, MUC16, CEACAM5
48giant cell glioblastoma10.2EGFR
49tuberculoid leprosy10.2IFNG, IL10
50xeroderma pigmentosum, variant type10.2ERCC1, BRCA1, TP53

Graphical network of the top 20 diseases related to Primary Peritoneal Carcinoma:



Diseases related to primary peritoneal carcinoma

Symptoms for Primary Peritoneal Carcinoma

About this section

Symptoms:

 48 (show all 9)
  • anomalies of the abdominal wall
  • nausea/vomiting/regurgitation/merycism/hyperemesis
  • acute abdominal pain/colic
  • constipation
  • peritoneal diseases
  • neoplasms/tumors
  • ovary/fallopian tube neoplasm/tumor/carcinoma/cancer (excl. teratoma/germinoma)
  • weight loss/loss of appetite/break in weight curve/general health alteration
  • early death/lethality

HPO human phenotypes related to Primary Peritoneal Carcinoma:

(show all 7)
id Description Frequency HPO Source Accession
1 weight loss hallmark (90%) HP:0001824
2 nausea and vomiting hallmark (90%) HP:0002017
3 constipation hallmark (90%) HP:0002019
4 abdominal pain hallmark (90%) HP:0002027
5 abnormality of the peritoneum hallmark (90%) HP:0002585
6 abnormality of the abdominal wall hallmark (90%) HP:0004298
7 ovarian neoplasm hallmark (90%) HP:0100615

Drugs & Therapeutics for Primary Peritoneal Carcinoma

About this section

Drug clinical trials:

Search ClinicalTrials for Primary Peritoneal Carcinoma

Search NIH Clinical Center for Primary Peritoneal Carcinoma

Genetic Tests for Primary Peritoneal Carcinoma

About this section

Anatomical Context for Primary Peritoneal Carcinoma

About this section

MalaCards organs/tissues related to Primary Peritoneal Carcinoma:

31
Ovary, Brain, Eye, Lymph node, Breast, Testes, Endothelial

Animal Models for Primary Peritoneal Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Primary Peritoneal Carcinoma:

35 (show all 24)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053708.7EGFR, ERCC1, IL10, IFNG, TP53
2MP:00053678.5BRCA1, RET, EGFR, TP53, ERCC1, IFNG
3MP:00053828.3TP53, IFNG, EGFR, IL10, ERBB2
4MP:00053718.3TP53, BRCA2, BRCA1, PGR, RET, IL10
5MP:00053888.3TP53, BRCA1, EGFR, ERBB2, IL10, IFNG
6MP:00030128.3TP53, PGR, RET, IFNG, IL10, EGFR
7MP:00053818.1ERBB2, EGFR, IL10, IFNG, TP53, BRCA2
8MP:00053697.9PGR, IL10, TP53, EGFR, ERCC1, ERBB2
9MP:00053867.9BRCA1, PGR, ERCC1, ERBB2, IL10, IFNG
10MP:00053907.9TP53, EGFR, IFNG, ERCC1, ERBB2, IL10
11MP:00107717.9TP53, EGFR, ERBB2, IL10, ERCC1, IFNG
12MP:00028737.9BRCA1, PGR, RET, IFNG, IL10, ERBB2
13MP:00053857.8ERBB2, BRCA1, PGR, CXCL10, IL10, EGFR
14MP:00036317.8TP53, BRCA2, BRCA1, CXCL10, RET, IFNG
15MP:00020067.7EGFR, ERCC1, ERBB2, IL10, IFNG, RET
16MP:00053797.7BRCA1, PGR, RET, IFNG, IL10, ERBB2
17MP:00053807.7ERCC1, TP53, BRCA2, IFNG, BRCA1, PGR
18MP:00053787.7IL10, IFNG, RET, BRCA1, BRCA2, TP53
19MP:00053897.7TP53, BRCA1, PGR, RET, IFNG, IL10
20MP:00053847.4ERBB2, CXCL10, RET, BRCA1, BRCA2, TP53
21MP:00053977.4IFNG, TP53, EGFR, ERCC1, IL8, IL10
22MP:00053877.4EGFR, ERCC1, IL8, IFNG, TP53, BRCA2
23MP:00053767.4ERCC1, TP53, EGFR, BRCA2, BRCA1, PGR
24MP:00107687.3PGR, BRCA1, BRCA2, TP53, EGFR, CXCL10

Publications for Primary Peritoneal Carcinoma

About this section

Articles related to Primary Peritoneal Carcinoma:

(show top 50)    (show all 108)
idTitleAuthorsYear
1
Cytoreductive surgery under aminolevulinic Acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial. (25056850)
2014
2
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. (24709487)
2014
3
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. (25016924)
2014
4
Solitary primary peritoneal carcinoma arising from the omentum. (25017281)
2014
5
Primary peritoneal carcinoma: regional cancer institute experience. (25419074)
2014
6
Treatment and prognostic factors in primary peritoneal carcinoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). (24903764)
2014
7
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma. (24798935)
2014
8
Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma. (24073344)
2013
9
Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. (23791702)
2013
10
The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma. (23146339)
2013
11
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (22710075)
2012
12
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (22446624)
2012
13
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. (22037316)
2012
14
Prognosis of primary peritoneal carcinoma: effect of cytoreductive surgery combined with neoadjuvant chemotherapy after laparoscopic diagnosis and evaluation: a multi-center trial. (22439406)
2012
15
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (22943879)
2012
16
Pax-8 is a reliable marker in making the diagnosis in advanced stage epithelial ovarian carcinoma and primary peritoneal carcinoma for neoadjuvant chemotherapy on cell block and biopsy specimens. (22348438)
2012
17
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. (22772063)
2012
18
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. (22047770)
2012
19
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (22155262)
2012
20
Primary peritoneal carcinoma in complete remission: a case report. (22199305)
2011
21
Peritoneal tuberculosis: a retrospective review of 20 cases and comparison with primary peritoneal carcinoma. (20973271)
2010
22
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. (20846715)
2010
23
The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review. (21045830)
2010
24
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. (19162309)
2009
25
RET/PTC rearrangement occurring in primary peritoneal carcinoma. (19147513)
2009
26
Primary peritoneal carcinoma in a young woman with suspected endometriosis. (19327764)
2009
27
Primary peritoneal carcinoma: computed tomography and magnetic resonance findings. (18664839)
2008
28
Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses. (18543395)
2008
29
Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. (17257661)
2007
30
Colorectal resection in patients with ovarian and primary peritoneal carcinoma. (16730631)
2006
31
Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period. (16515579)
2006
32
Primary peritoneal carcinoma: a rare neoplasm with pleomorphic trophoblastic morphology. (16907865)
2006
33
Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma. (16769104)
2006
34
Asymptomatic primary peritoneal carcinoma presenting as adenocarcinoma on routine cervical cytology. (16553187)
2006
35
Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels. (16564077)
2006
36
Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. (15589582)
2005
37
Is semen an etiologic factor in the development of primary peritoneal carcinoma and epithelial ovarian cancer? (15607552)
2005
38
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. (14615451)
2003
39
Axillary lymphadenopathy as the primary presentation of primary peritoneal carcinoma. (12592068)
2002
40
Prolonged symptom-free survival in a patient with persistent primary peritoneal carcinoma and a rising CA-125: a note of caution. (11371148)
2001
41
Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma. (10738268)
2000
42
Solitary brain metastasis indicating recurrent primary peritoneal carcinoma. (10912420)
1999
43
Importance of lymph node metastases in primary peritoneal carcinoma. (9701204)
1998
44
Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. (9692840)
1998
45
Extraovarian primary peritoneal carcinoma. (9644683)
1998
46
Prognostic factors in extraovarian primary peritoneal carcinoma. (9826465)
1998
47
Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. (9367697)
1997
48
Primary peritoneal carcinoma: a treatable subset of patients with adenocarcinoma of unknown primary. (8602811)
1996
49
Surgically documented responses to paclitaxel and cisplatin in patients with primary peritoneal carcinoma. (8690292)
1996
50
Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. (8467455)
1993

Variations for Primary Peritoneal Carcinoma

About this section

Expression for genes affiliated with Primary Peritoneal Carcinoma

About this section
Search GEO for disease gene expression data for Primary Peritoneal Carcinoma.

Pathways for genes affiliated with Primary Peritoneal Carcinoma

About this section

Pathways related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 53)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
10.0BRCA1, BRCA2
29.8TP53, BRCA1
39.8TP53, BRCA1
49.8IL10, IFNG
5
Show member pathways
9.7ERCC1, BRCA2, BRCA1
69.7BRCA2, BRCA1, ERCC1
79.7EGFR, IL8
89.6RET, IL10, IL8
99.5IFNG, IL8, BRCA1
10
Show member pathways
9.5TP53, BRCA2, BRCA1
119.5TP53, BRCA2, BRCA1
12
Show member pathways
Transcription NF kB signaling pathway59
Immune response Toll like receptor TLR ligands and common TLR signaling pathway leading to cell proinflammatory response59
9.5IFNG, CXCL10, IL8
13
Show member pathways
Development ERBB family signaling59
Development GDNF family signaling59
9.5RET, EGFR, ERBB2
149.5ERBB2, RET, EGFR
159.4IL8, IFNG, IL10
169.4IFNG, IL10, IL8
179.4IFNG, IL10, IL8
189.4ERBB2, EGFR, IFNG
199.3TP53, ERBB2, EGFR
20
Show member pathways
9.3ERBB2, TP53, EGFR
21
Show member pathways
9.3ERBB2, TP53, EGFR
229.3EGFR, ERBB2, TP53
23
Show member pathways
ErbB receptor signaling network36
ErbB signaling pathway36
9.3EGFR, TP53, ERBB2
24
Show member pathways
Signal transduction PTEN pathway59
9.3TP53, ERBB2, EGFR
259.3IL8, IFNG, TP53
269.3IL8, IFNG, TP53
27
Show member pathways
Immune response MIF in innate immunity response59
9.3TP53, IL8, IFNG
28
Show member pathways
9.3BRCA2, TP53, BRCA1, ERCC1
29
Show member pathways
9.3BRCA2, TP53, BRCA1, ERCC1
309.3IL8, TP53, EGFR
31
Show member pathways
9.2TP53, EGFR, IFNG
329.2TP53, EGFR, IFNG
339.1BRCA2, BRCA1, EGFR, TP53
34
Show member pathways
9.1IFNG, IL8, TP53, CXCL10
35
Show member pathways
9.0EGFR, BRCA2, ERBB2, TP53
36
Show member pathways
8.9ERBB2, IFNG, TP53, EGFR
378.9MIR195, MIR497, TP53
38
Show member pathways
8.9CXCL10, IL8, IL10, ERBB2, EGFR
39
Show member pathways
8.8BRCA2, TP53, BRCA1, ERBB2, EGFR
408.8TP53, BRCA2, BRCA1, ERBB2, EGFR
41
Show member pathways
Toll-like receptor signaling pathway36
Regulation of toll-like receptor signaling pathway36
8.7IL8, IL10, IFNG, CXCL10, TP53
428.7EGFR, CXCL10, IFNG, IL8, TP53
43
Show member pathways
Signaling Pathways in Glioblastoma36
8.5IL8, BRCA2, BRCA1, ERBB2, EGFR, TP53
448.5ERBB2, EGFR, MIR195, BRCA1, TP53
45
Show member pathways
8.5PGR, TP53, CXCL10, IL8, ERBB2, EGFR
468.4TP53, BRCA2, RET, IL8, ERBB2, EGFR
47
Show member pathways
8.4EGFR, IL8, IL10, CXCL10, TP53, ERBB2
48
Show member pathways
8.2CXCL10, EGFR, TP53, IL10, IL8, ERBB2
49
Show member pathways
8.0IL10, IFNG, BRCA1, IL8, TP53, EGFR
50
Show member pathways
8.0EGFR, ERBB2, IL8, TP53, CXCL10, IFNG

Compounds for genes affiliated with Primary Peritoneal Carcinoma

About this section

Compounds related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 175)
idCompoundScoreTop Affiliating Genes
1topotecan44 1110.7EGFR, MUC16, BRCA1
2vinorelbine44 50 1111.7EGFR, ERCC1, ERBB2, BRCA1
3fluticasone propionate44 50 60 1112.5IFNG, IL8, CXCL10, PGR
4polyinosinic-polycytidylic acid449.5IL10, IFNG, CXCL10, IL8
5capecitabine44 50 1111.5EGFR, ERBB2, PGR
6il 10449.4CXCL10, IFNG, IL10, IL8
7tarc449.4IL8, IFNG, IL10, CXCL10
8taxane449.4EGFR, TP53, PGR, ERBB2
9ccl344 2810.4CXCL10, IFNG, IL10, IL8
10neopterin449.3IL8, IL10, CXCL10, IFNG
11resveratrol44 60 24 1112.3PGR, ERBB2, BRCA1, BRCA2, TP53
12hydrocortisone44 1 60 1112.2IL10, IFNG, ERBB2, IL8, CXCL10
13methotrexate50 44 1111.2IL10, PGR, ERBB2, BRCA2, BRCA1, ERCC1
14suberoylanilide hydroxamic acid449.2EGFR, ERBB2, IFNG, TP53
15bortezomib44 50 1111.2EGFR, BRCA1, ERBB2, TP53
16herbimycin a44 6010.1RET, IFNG, IL8, ERBB2, EGFR
174-hydroxytamoxifen449.0ERBB2, BRCA1, PGR, IFNG, BRCA2, EGFR
18melphalan44 50 1111.0ERCC1, TP53, MUC16, IFNG
19etoposide44 50 60 1112.0BRCA2, ERCC1, ERBB2, BRCA1, TP53
20gemcitabine44 50 1110.9IL10, ERBB2, TP53, ERCC1, EGFR, BRCA1
21thymidylate448.9TP53, BRCA1, IL10, ERBB2, ERCC1, EGFR
22tamoxifen44 50 28 1111.9BRCA2, BRCA1, PGR, ERBB2, EGFR, TP53
23leucovorin44 50 1110.8CEACAM5, EGFR, ERCC1, ERBB2, PGR
24docetaxel44 50 60 1111.7TP53, EGFR, BRCA2, BRCA1, PGR, ERCC1
25gold448.7CXCL10, BRCA2, CEACAM5, BRCA1, MUC16
26ly294002448.7ERBB2, IL8, RET, IL10, TP53, EGFR
27irinotecan44 50 1110.6ERCC1, ERBB2, EGFR, CEACAM5, TP53
28cyclophosphamide44 50 1110.6TP53, BRCA1, PGR, MUC16, ERCC1, IL10
29agar448.6ERBB2, CEACAM5, RET, PGR, EGFR, BRCA1
30mitomycin c448.6TP53, BRCA2, ERCC1, BRCA1, CEACAM5, IL10
31testosterone44 60 24 1111.5BRCA1, PGR, MUC16, ERBB2, EGFR, BRCA2
32adriamycin448.5ERBB2, CEACAM5, TP53, BRCA2, PGR, BRCA1
33sb 20358044 609.5IL8, EGFR, IFNG, TP53, IL10
34oxaliplatin44 50 1110.5BRCA1, TP53, CEACAM5, ERBB2, ERCC1, EGFR
35carboplatin44 50 1110.4ERBB2, ERCC1, BRCA1, EGFR, IFNG, MUC16
36dexamethasone44 50 28 1111.4CXCL10, IFNG, IL10, IL8, PGR, MUC16
37retinoic acid44 249.3BRCA2, PGR, CXCL10, RET, IFNG, EGFR
38genistein44 28 60 1 24 1113.2CXCL10, IL8, EGFR, ERBB2, IFNG, RET
39paclitaxel44 50 1110.2ERBB2, BRCA1, ERCC1, EGFR, MUC16, PGR
40phosphatidylinositol448.1ERBB2, CEACAM5, RET, CXCL10, BRCA1, BRCA2
41thymidine44 248.9BRCA1, IL10, ERCC1, IFNG, TP53, CEACAM5
42butyrate447.9TP53, RET, IFNG, IL8, CEACAM5
435fluorouracil447.8PGR, BRCA1, CEACAM5, EGFR, ERCC1, TP53
44cycloheximide447.7CXCL10, PGR, BRCA1, BRCA2, IL10, ERBB2
45doxorubicin44 50 119.6EGFR, ERBB2, CEACAM5, MUC16, PGR, BRCA1
46cisplatin44 50 60 1110.6BRCA2, BRCA1, MUC16, CEACAM5, ERBB2, ERCC1
47progesterone44 28 60 24 1111.4EGFR, ERBB2, TP53, BRCA2, BRCA1, PGR
48estrogen447.1EGFR, CEACAM5, TP53, BRCA2, BRCA1, ERCC1
49paraffin447.1TP53, BRCA1, PGR, MUC16, RET, CEACAM5
50vegf446.1EGFR, TP53, BRCA1, ERBB2, IL8, IL10

GO Terms for genes affiliated with Primary Peritoneal Carcinoma

About this section

Cellular components related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1receptor complexGO:00432359.6EGFR, ERBB2, RET
2transcription factor TFIID complexGO:00056699.5TP53, ERCC1
3endosome membraneGO:00100089.4EGFR, ERBB2, RET
4nucleoplasmGO:00056549.0ERCC1, PGR, BRCA1, BRCA2, TP53
5basolateral plasma membraneGO:00163238.9CEACAM5, ERBB2, EGFR
6extracellular spaceGO:00056158.4EGFR, MUC16, CXCL10, IFNG, IL10, IL8

Biological processes related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 23)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of MHC class II biosynthetic processGO:004534810.1IL10, IFNG
2response to molecule of bacterial originGO:000223710.0IL10, IL8
3embryonic organ developmentGO:004856810.0TP53, ERCC1
4negative regulation of growth of symbiont in hostGO:004413010.0IL10, IFNG
5DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:00069789.9TP53, BRCA1, BRCA2
6positive regulation of cell cycle arrestGO:00711589.9BRCA1, TP53
7cellular response to estradiol stimulusGO:00713929.9IL10, EGFR
8response to X-rayGO:00101659.9ERCC1, TP53, BRCA2
9response to gamma radiationGO:00103329.9TP53, CXCL10, BRCA2
10nucleotide-excision repairGO:00062899.8TP53, BRCA2, ERCC1
11peptidyl-tyrosine phosphorylationGO:00181089.8RET, ERBB2, EGFR
12cell agingGO:00075699.8TP53, BRCA2
13cellular response to lipopolysaccharideGO:00712229.7IFNG, IL8, IL10
14double-strand break repairGO:00063029.6BRCA2, BRCA1, ERCC1, TP53
15positive regulation of DNA repairGO:00457399.5EGFR, BRCA1
16protein import into nucleus, translocationGO:00000609.5TP53, IFNG
17cell surface receptor signaling pathwayGO:00071669.5CXCL10, IFNG, ERBB2, EGFR
18cell cycle arrestGO:00070509.4IFNG, TP53, IL8
19cell proliferationGO:00082839.3ERCC1, EGFR, ERBB2, TP53
20positive regulation of transcription, DNA-templatedGO:00458939.3RET, IL10, BRCA1, TP53, BRCA2
21signal transductionGO:00071659.0ERBB2, PGR, EGFR, IL8, RET, CXCL10
22positive regulation of transcription from RNA polymerase II promoterGO:00459448.8BRCA1, CXCL10, TP53, IFNG, IL10, EGFR
23negative regulation of apoptotic processGO:00430668.5TP53, CEACAM5, EGFR, IL10

Molecular functions related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1epidermal growth factor-activated receptor activityGO:00050069.9EGFR, ERBB2
2transmembrane receptor protein tyrosine kinase activityGO:00047149.7EGFR, ERBB2, RET
3receptor signaling protein tyrosine kinase activityGO:00047169.5ERBB2, EGFR
4protein tyrosine kinase activityGO:00047139.4EGFR, ERBB2, RET
5protein phosphatase bindingGO:00199039.3TP53, ERBB2, EGFR
6enzyme bindingGO:00198999.2TP53, BRCA1, PGR, EGFR
7identical protein bindingGO:00428028.5EGFR, ERBB2, CEACAM5, TP53
8protein bindingGO:00055157.1PGR, BRCA1, BRCA2, TP53, MUC16, CXCL10

Sources for Primary Peritoneal Carcinoma

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet